STRATA Skin Sciences, Inc. Stock News

Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market growth and expanding indications Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued marke...

HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shar...

Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Dolev Rafaeli - President, CEO & Vice-Chairman John Gillings - Principal Financial Officer & Chief Accounting Officer Conference Call Participants Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Jeremy Pearlman - Maxim Group LLC, Research Division Jul...

Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment STRATA updates status of non-Excimer laser false advertising litigation HORSHAM, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for ...

HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close.

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jules Abraham - CORE IR Dolev Rafaeli - Chief Executive Officer John Gillings - VP of Finance Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jeremy Pearlman - Maxim Group Operator Good afternoon, and welcome to the STRATA Skin Sciences First Quarter 2025 Finan...

HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update.